STOCK TITAN

ICU Medical (ICUI) Stock Price, News & Analysis

ICUI NASDAQ
Published by Stock Titan Data refreshed

Price Move History

Daily moves over 5%
4 252 sessions, November 17, 2025 to November 17, 2026
Largest daily move
+10.9% close of August 7, 2026
1-year change
+31.5% closing prices, November 17, 2025 to November 17, 2026
1-month change
+8.5% closing prices, October 16, 2026 to November 17, 2026

Company Description

ICU Medical, Inc. (Nasdaq: ICUI) is a medical technology company that focuses on the development, manufacture and sale of medical products used across a range of care settings. According to the company’s public disclosures, ICU Medical is described as a global leader in infusion systems, infusion consumables and high-value critical care products that are used in hospital, alternate site and home care environments. The company is headquartered in San Clemente, California.

ICU Medical’s business centers on products that support infusion therapy and critical care. In its communications to investors, the company highlights three primary product groupings: consumables, infusion systems and vital care. These categories are also used in the company’s financial reporting, where revenue is broken out by product line. Consumables, infusion systems and vital care together represent the core of ICU Medical’s operations and reflect its focus on clinically essential devices and related products.

The company’s financial reports show that it generates revenue by selling these medical products to clinical customers. ICU Medical notes that its team is focused on providing quality, innovation and value to clinical customers worldwide, and that its products are used in hospital, alternate site and home care settings. The company’s disclosures also state that it offers clinically essential medical devices that connect patients and caregivers through technology and services intended to provide meaningful clinical value.

ICU Medical reports its results by product line, which provides insight into how its operations are organized. The company discloses revenues for Consumables, Infusion Systems and Vital Care in its quarterly financial statements. These product lines include, among other things, infusion-related products and critical care offerings. The company has also disclosed that certain contract manufacturing activities and IV solutions-related revenue have been included within the Vital Care product line in specific periods.

In addition to its core product categories, ICU Medical has engaged in strategic transactions related to IV solutions. The company’s financial disclosures for 2025 describe an IV Solutions business that was included within the Vital Care product line and note that this business was disposed of on May 1, 2025. Separately, ICU Medical announced the formation of Otsuka ICU Medical LLC, a joint venture with Otsuka Pharmaceutical Factory, Inc. aimed at strengthening IV solutions manufacturing and innovation in the North American market. Under the terms of that joint venture, ICU Medical states that it will provide commercial services for the venture to support North American customers.

ICU Medical’s public statements also emphasize its role in IV solutions supply and manufacturing. In connection with the joint venture with Otsuka Pharmaceutical Factory, the company described the partnership as creating one of the largest global IV solutions manufacturing networks, with combined production of an estimated 1.4 billion annual units, and as intended to enhance supply chain resiliency and introduce new technologies to the North American IV solutions market. These disclosures highlight the importance of IV solutions and related products within the broader context of ICU Medical’s business.

The company’s financial filings and press releases provide further detail on its operations. ICU Medical reports on metrics such as total revenues, cost of goods sold, gross profit, operating expenses, and segment-level revenues for consumables, infusion systems and vital care. It also discusses items such as restructuring, strategic transaction and integration expenses, research and development spending, and the impact of contract manufacturing arrangements. While specific figures change over time, these disclosures indicate that ICU Medical’s business model is built around manufacturing and selling medical devices and products that support infusion therapy and critical care.

ICU Medical’s securities are listed on the Nasdaq Global Select Market under the symbol ICUI. The company files periodic reports and current reports with the U.S. Securities and Exchange Commission, including Forms 10-K, 10-Q and 8-K. In its forward-looking statements sections, ICU Medical identifies a range of risks related to its operations, such as competition, demand for its products, costs related to product development, supply chain considerations, regulatory matters, and macroeconomic and healthcare-specific factors. These disclosures provide additional context for understanding the environment in which the company operates.

Overall, ICU Medical can be characterized, based on its own public descriptions, as a manufacturer of clinically essential infusion and critical care products that are used across multiple care settings. Its reported product lines of consumables, infusion systems and vital care, along with its involvement in IV solutions manufacturing and joint ventures, frame the company’s role within the surgical and medical instrument manufacturing industry.

Business segments and product focus

ICU Medical’s financial reporting highlights three main product lines:

  • Consumables – infusion-related consumable products, reported as a distinct product line in the company’s revenue disclosures.
  • Infusion Systems – infusion systems products, which the company identifies as a separate revenue category.
  • Vital Care – vital care products, including, in certain periods, IV Solutions revenue and contract manufacturing revenue as disclosed in the company’s financial statements.

These product lines are central to how ICU Medical presents its business to investors and regulators, and they align with the company’s description of itself as a global leader in infusion systems, infusion consumables and high-value critical care products.

Industry classification

Based on the provided classification, ICU Medical operates in the Surgical and Medical Instrument Manufacturing industry within the broader Manufacturing sector. Its focus on infusion therapy products, consumables and critical care devices places it within the medical device and equipment segment of this industry.

Stock Performance

$176.91
-2.73%
-4.96
Last updated: at
+31.5%
Performance 1 year

ICU Medical (ICUI) closed at $176.91 on November 17, 2026. Over the past 12 months, the price has gained 31.5%.

See what a $1,000 investment in ICUI would be worth today

Average down calculator for ICUI

ICUI Metrics & Rankings

Price returns through November 17, 2026. Month and year figures include the first trading day. Ranking links may use different dates.

Insider Radar

Net Sellers
90-Day Summary
0
Shares Bought
22,309
Shares Sold
11
Transactions
Most Recent Transaction
FINNEY ELISHA W (Director) sold 1,700 shares @ $179.00 on November 13, 2026

Insider selling at ICU Medical over the past 90 days can reflect routine portfolio management, scheduled trading plans (Rule 10b5-1), tax planning, or compensation-related dispositions rather than a directional view on the stock.

Based on SEC Form 4 filings over the last 90 days.

Financial Highlights

ICU Medical generated $2.2B in revenue in FY2025, retaining a 36.8% gross margin, operating income reached $42.8M (1.9% operating margin), and net income was $732K, reflecting a 0.0% net profit margin. Diluted earnings per share stood at $0.03. The company generated $179.8M in operating cash flow. The current ratio was 2.39, measuring current assets divided by current liabilities.

$2.2B
Revenue (FY2025)
$732K
Net Income (FY2025)
$179.8M
Operating Cash Flow

Upcoming Events

NOV
18
November 18, 2026 Marketing

Jefferies presentation

ICU Medical presentation at Jefferies Global Healthcare Conference in London on Nov 18; live webcast and replay via investor website; one-on-ones that day.

ICU Medical has 1 upcoming scheduled event. The next event, "Jefferies presentation", is scheduled for November 18, 2026 (tomorrow). Investors can track these dates to stay informed about potential catalysts that may affect the ICUI stock price.

Short Interest History

Last 12 Months

Short interest in ICU Medical (ICUI) currently stands at 1.7 million shares, down 2.4% from the previous reporting period, representing 6.8% of the float. Since November 2025, short interest has increased by 26.3%.

Days to Cover History

Last 12 Months

Days to cover for ICU Medical (ICUI) currently stands at 8.0 days. The ratio is the reported short interest divided by the average daily trading volume. Since November 2025, the figure has increased by 54.2%. Across the settlements charted above, it has ranged from 3.5 to 8.0 days.

ICUI Company Profile & Sector Positioning

ICU Medical (ICUI) operates in the Medical Instruments & Supplies industry within the broader Healthcare sector and is listed on the NASDAQ.

Investors comparing ICUI often look at related companies in the same sector, including Stevanato Group S.p.A. (STVN), Envista Holdings Corporation (NVST), Merit Medical Systems Inc (MMSI), MiniMed Group, Inc. (MMED), and Pulse Biosciences, Inc (PLSE). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate ICUI's relative position within its industry.

Frequently Asked Questions

The current stock price of ICU Medical (ICUI) is $176.91 as of November 17, 2026.

The market cap of ICU Medical (ICUI) is approximately $4.4B. Learn more about what market capitalization means .

The FY2025 revenue of ICU Medical (ICUI) is $2.2B, from its most recent completed fiscal year.

The FY2025 net income of ICU Medical (ICUI) is $732K, from its most recent completed fiscal year.

The diluted earnings per share (EPS) of ICU Medical (ICUI) is $0.03 for FY2025, its most recent completed fiscal year. Learn more about EPS .

The operating cash flow of ICU Medical (ICUI) is $179.8M for FY2025, its most recent completed fiscal year. Learn about cash flow.

The net profit margin of ICU Medical (ICUI) is 0.0% for FY2025, its most recent completed fiscal year. Learn about profit margins.

The operating profit margin of ICU Medical (ICUI) is 1.9% for FY2025, its most recent completed fiscal year. Learn about operating margins.

The gross profit margin of ICU Medical (ICUI) is 36.8% for FY2025, its most recent completed fiscal year. Learn about gross margins.

The current ratio of ICU Medical (ICUI), current assets divided by current liabilities, was 2.39 at the end of FY2025, its most recent completed fiscal year. Learn about liquidity ratios.

The gross profit of ICU Medical (ICUI) is $822.0M for FY2025, its most recent completed fiscal year.

The operating income of ICU Medical (ICUI) is $42.8M for FY2025, its most recent completed fiscal year. Learn about operating income.

ICU Medical, Inc. focuses on the development, manufacture and sale of medical products, with an emphasis on infusion systems, infusion consumables and high-value critical care products used in hospital, alternate site and home care settings.

The company describes itself as a global leader in infusion systems, infusion consumables and high-value critical care products. In its financial reporting, it organizes revenue into three product lines: Consumables, Infusion Systems and Vital Care.

ICU Medical operates in the Surgical and Medical Instrument Manufacturing industry within the broader Manufacturing sector.

ICU Medical states that it is headquartered in San Clemente, California.

ICU Medical’s common stock is listed on the Nasdaq Global Select Market under the ticker symbol ICUI.

In its quarterly financial statements, ICU Medical reports revenues for three product lines: Consumables, Infusion Systems and Vital Care.

ICU Medical has disclosed that IV Solutions revenue was included within its Vital Care product line and that it disposed of its IV Solutions business on May 1, 2025. The company also participates in an IV solutions-focused joint venture with Otsuka Pharmaceutical Factory, Inc.

According to a joint announcement, Otsuka ICU Medical LLC is intended to strengthen IV solutions supply chain resiliency and drive innovation in the North American IV solutions market, combining Otsuka Pharmaceutical Factory’s manufacturing scale with ICU Medical’s North American production and commercial services.

ICU Medical states that its infusion systems, infusion consumables and high-value critical care products are used in hospital, alternate site and home care settings.

Through its SEC filings and earnings press releases, ICU Medical provides information on total revenues, cost of goods sold, gross profit, operating expenses, net income or loss, product line revenues, cash flows and non-GAAP measures such as adjusted EBITDA and adjusted diluted earnings per share.